Sanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow Post author:Sam Post published:November 29, 2017 Post category:BioPharma Sanofi’s setback could open the door for rival drugmaker Takeda. Source: BioSpace You Might Also Like George Scangos' Bold Vision October 24, 2017 FDA Gives Go-Ahead for Tetra's Phase II Trial March 15, 2018 Seattle Genetics, Immunomedics Ink $2 Billion Tumor Drug Deal February 9, 2017
